Alogliptin May Be Associated With Lower Fracture Risk Compared With Linagliptin, Saxagliptin
The DPP-4 inhibitor alogliptin may be associated with a lower risk for bone fracture compared with linagliptin and saxagliptin.
The risk for fragility fractures is significantly lower in women with osteopenia who receive zoledronate than in those who receive placebo.
Fifteen genetic determinants of fracture, which are also associated with bone mineral density, have been identified.
Investigators assess whether circulating advanced glycation end products and esRAGE were associated with bone turnover and risk for fracture.